ROTARIXTM is celebrating its 1st birthday
Abstract
It’s been one year since launch and ROTARIXTM is celebrating. Data from a recent study announced at ESPID (European Society for Paediatric Infectious Diseases) showed that ROTARIXTM, the first oral rotavirus vaccine available to children in South Africa, protects against up to 96% of severe rotavirus gastroenteritis (RVGE) cases and prevents up to 100% of hospitalisations due to rotavirus-induced gastroenteritis in a European setting.
Issue
Section
Press releases
By submitting manuscripts to PNT, authors of original articles are assigning copyright to Medpharm Publications (Pty) Ltd. Authors may use their own work after publication without written permission, provided they acknowledge the original source. Individuals and academic institutions may freely copy and distribute articles published in PNT for educational and research purposes without obtaining permission.
